CLEC1B and osteosarcoma: In Osteosarcoma models expressing PDPN, anti-CLEC-2 monoclonal antibody (2A2B10) treatment reduced plasma concentrations of key pro-inflammatory cytokines and suppressed lung metastasis relative to control mice (35).